Alice Bendix Gottlieb, MD/PhD
Taltz: Perscpectives from Dual Specialties
Dr. Gottlieb is an internationally recognized expert and leader in the field of psoriasis, psoriatic arthritis, and hidradenitis suppurativa. She obtained her MD from Cornell Medical School and her PhD in immunology from the Rockefeller University, where she studied in the laboratory of Henry Kunkel and was one of the first females admitted to Rockefeller University’s joint MD/PhD program.
She was one of the first scientists to demonstrate that psoriasis is a T-cell mediated disease.
Dr. Gottlieb has received numerous awards for her work, including the American Skin Association’s
Psoriasis Research Award, the Honorary Fellowship Award of the American College of Clinical
Pharmacology, and the National Psoriasis Foundation’s Outstanding Educator in Psoriatic Disease
Award. In November 2015, she was the first female scientist featured on the cover in the Journal
of Investigative Dermatology’s series on translational research scientists.
Her research using targeted immunobiologics as pathogenic probes provided new understanding
of the pathogenesis of psoriasis and provided the foundation for biologic drug development in
psoriasis and psoriatic arthritis. Her translational research provided the first double-blind,
randomized, placebo-controlled study of the efficacy of TNF blockers as monotherapy for moderate
to severe psoriasis (published in Lancet in 2001). Most recently, she co-authored the phase
3 studies of a TNF blocker, adalimumab, for treatment of hidradenitis suppurativa, which were
published in the New England Journal of Medicine. She is triple boarded in dermatology,
rheumatology, and internal medicine, and is one of only a handful of doctors in the US to be
certified in all three of these specialties. Currently, Dr. Gottlieb’s research centers on developing
new treatments for psoriasis and psoriatic arthritis, developing better outcome measures for
psoriasis, and on understanding the mechanisms of action of these novel agents. Additionally,
she is working on initiatives to prevent disability due to psoriatic arthritis and to develop outcome
measures useful to all stakeholders and useful in clinical practice.
Dr. Gottlieb was on the Board of Directors of the American Academy of Dermatology for 2011-
- She is the founder and President of the Board of the International Dermatology Outcome
Measures (IDEOM) group, active in the autoimmune disease community as a councilor of the
International Psoriasis Council, a member of the Executive and Steering Committees of GRAPPA
(an international psoriatic arthritis coalition), a Medical Advisory Board member and Co-Editor of
the Journal of Psoriasis and Psoriatic Arthritis, and on the editorial board of Dermatology.